SYGNIS Pharma AG Secures Further Financial Resources With New Investors Loan
7/8/2013 9:29:55 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Heidelberg, 8 July 2013 - SYGNIS Pharma AG (Frankfurt: LIO1; ISIN:
DE000A1RFM03, Prime Standard) today reports on the granting of a loan for
a total amount of up to EUR 0.55 million by a group of international investors
comprising the Bedford Investment Fund, George Town, Cayman Islands,
The Excalibur Investments Fund, George Town, Cayman Islands and
Casticapital, S.L., Las Palmas de Gran Canaria, Spain, as well as
Mr. Gonzalo Rodríguez-Fraile Díaz, who is a member of the Supervisory
Board of SYGNIS Pharma AG. Another member of the Supervisory Board of
SYGNIS Pharma AG, Mr. Pedro-Agustín del Castillo Machado, is Chairman of
the Board of Directors of Casticapital, S.L.
The loan bears interest at customary market conditions. The loan, which is
payable on demand, secures the financing of SYGNIS’ existing operations,
according to the present plans, until mid September 2013. The loan is
secured and is due for repayment not before the end of 2014.
Under the loan agreement, the international investors may, subject to certain
conditions, participate in a possible future capital increase of SYGNIS by
subscribing for newly issued SYGNIS shares from the Company's authorized
For further information please contact:
SYGNIS Pharma AG
Pilar de la Huerta
This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy
securities. Some statements included in this press release, relating neither to proven financial results nor other
historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of
future results, trends, plans or goals. These statements should not be considered to be total guarantees since given
their very nature they are subject to known and unknown risks and imponderability and can be affected by other
factors as a consequence of which the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly
from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to
publicly update or revise these statements in the light of new information or future results or for any other reason.
Help employers find you! Check out all the jobs and post your resume.
comments powered by